Table 1.
Clinical and laboratory characteristics of study groups before treatment.
| Group A (n = 65) | Group B (n = 65) | p-values | |
|---|---|---|---|
| Gender | |||
| Male/Female | 57/8 | 62/3 | 0.207 |
| Age | |||
| Median (95% CI) | 22.0 (21.0–25.5) | 24.0 (21.5–28.5) | 0.226 |
| Min-Max | 15–50 | 15–54 | |
| Body weight (kg) | |||
| Median (95% CI) | 50.0 (48.7–52.0) | 51.8 (49.1–53.7) | 0.103 |
| Min-Max | 40.5–70.0 | 40.1–74.0 | |
| Fever [Median (95% CI)] | |||
| Duration before admission (days) | 3.0 (2.0–4.5) | 3.0 (2.5–4.0) | 0.270 |
| Highest fever before treatment (°C) | 37.8 (37.6–37.9) | 37.8 (37.5–37.9) | 0.587 |
| Number of patients with: | |||
| Splenomegaly | 12 | 14 | 0.661 |
| Hepatomegaly | 43 | 38 | 0.365 |
| Geometric mean initial parasites count (/μl) | 12,585 | 10,902 | 0.208 |
| Min-Max | 120–147,730 | 104–134,580 | |
| Laboratory data [median (95% CI)] | |||
| Hematocrit (%) | 37.1 (34.8–.9) | 38.3 (34.4–39.2) | 0.224 |
| White blood cell count (103/μl) | 5.15 (4.88–5.70) | 5.40 (5.04–5.89) | 0.332 |
| Platelet count (103/μl) | 101.0 (97.8–130.0) | 112.0 (95.3–139.6) | 0.142 |
| Total bilirubin (mg %) | 0.80 (0.65–1.14) | 0.70 (0.66–1.15) | 0.192 |
| Aspartate aminotransferase (U/l) | 25.0 (21.7–43.2) | 22.0 (21.3–39.6) | 0.227 |
| Alanine aminotransferase (U/l) | 23.0 (21.7–41.4) | 24.0 (22.8 –43.5) | 0.697 |
| Blood urea nitrogen (mg %) | 13.0 (12.1–14.0) | 13.4 (12.9–14.7) | 0.306 |
| Creatinine (mg %) | 0.78 (0.73–0.87) | 0.80 (0.70–0.85) | 0.124 |